We are live on ! Find out more
INDP icon

Indaptus Therapeutics
INDP

14 hedge funds and large institutions have $1.08M invested in Indaptus Therapeutics in 2023 Q1 according to their latest regulatory filings, with 1 funds opening new positions, 2 increasing their positions, 1 reducing their positions, and 3 closing their positions.

New
Increased
Maintained
Reduced
Closed

100% more repeat investments, than reductions

Existing positions increased: 2 | Existing positions reduced: 1

24% more capital inflows, than outflows

Capital inflows: $75.6K | Capital outflows: $60.8K

0.08% less ownership

Funds ownership: 6.98% → 6.9% (-0.08%)

13% less funds holding

Funds holding: 16 → 14 (-2)

67% less first-time investments, than exits

New positions opened: 1 | Existing positions closed: 3

Holders
14
Holders Change
-2
Holders Change %
-12.5%
% of All Funds
0.22%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
1
Increased
2
Reduced
1
Closed
3
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Morgan Stanley
Morgan Stanley
New York
+$519
2
Renaissance Technologies
Renaissance Technologies
New York
+$189

Top Sellers

Rank Fund Capital Flow
1
Stratos Wealth Partners
Stratos Wealth Partners
Ohio
-$38.9K
2
Susquehanna International Group
Susquehanna International Group
Pennsylvania
-$20.9K
3
Tower Research Capital (TRC)
Tower Research Capital (TRC)
New York
-$1.04K
4
Bank of America
Bank of America
North Carolina
-$16

INDP Hedge Fund Activity: Q1 2023 in Review

14 of the 6,289 institutional investors tracked by Wall St. Rank reported a position in Indaptus Therapeutics (INDP) for Q1 2023, worth a combined $1.08M — up 29% from $839K a quarter earlier.

Sellers outnumbered buyers: 3 funds closed out of INDP and 1 opened new positions — a net loss of 2 holders — while 1 trimmed existing stakes and 2 added.

The largest buyer was Morgan Stanley, adding an estimated $519. The largest seller was Stratos Wealth Partners, exiting entirely with an estimated $38.9K sold.

  • 14 institutional investors held Indaptus Therapeutics (INDP) as of Q1 2023, down from 16 in Q4 2022.
  • Funds reported $1.08M of Indaptus Therapeutics stock for Q1 2023, up 29% quarter-over-quarter.
  • 1 fund opened new Indaptus Therapeutics positions in Q1 2023 and 3 closed out, a net change of -2 holders.
  • The largest Indaptus Therapeutics buyer in Q1 2023 was Morgan Stanley, an estimated $519 added.
  • The largest Indaptus Therapeutics seller in Q1 2023 was Stratos Wealth Partners, an estimated $38.9K sold.

Based on aggregated 13F filings for Q1 2023.